ProQR Therapeutics (PRQR) Enterprise Value (2021 - 2024)
Historic Enterprise Value for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to -$159.7 million.
- ProQR Therapeutics' Enterprise Value fell 2477.45% to -$159.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$159.7 million, marking a year-over-year decrease of 2477.45%. This contributed to the annual value of -$161.7 million for FY2024, which is 2570.42% down from last year.
- ProQR Therapeutics' Enterprise Value amounted to -$159.7 million in Q4 2024, which was down 2477.45% from -$128.0 million recorded in Q4 2023.
- In the past 5 years, ProQR Therapeutics' Enterprise Value ranged from a high of -$91.5 million in Q1 2021 and a low of -$219.1 million during Q4 2021
- Its 4-year average for Enterprise Value is -$150.5 million, with a median of -$149.8 million in 2023.
- Within the past 5 years, the most significant YoY rise in ProQR Therapeutics' Enterprise Value was 5527.8% (2022), while the steepest drop was 11478.21% (2022).
- ProQR Therapeutics' Enterprise Value (Quarter) stood at -$219.1 million in 2021, then surged by 55.28% to -$98.0 million in 2022, then crashed by 30.59% to -$128.0 million in 2023, then decreased by 24.77% to -$159.7 million in 2024.
- Its Enterprise Value was -$159.7 million in Q4 2024, compared to -$128.0 million in Q4 2023 and -$131.5 million in Q3 2023.